<!DOCTYPE html><html lang="en"><head>
		<meta charset="utf-8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		
		<link href="../../_app/immutable/assets/0.593d50ad.css" rel="stylesheet"><title>Novo Nordisk A/S (NVO) Stock Price, Quote &amp; News - Stock Analysis</title><!-- HEAD_svelte-kmiyj1_START --><script defer="" data-api="/cfa/event/" data-domain="stockanalysis.com" event-is_logged_in="false" event-is_pro="false" src="/cfa/js/script.js"></script><script data-svelte-h="svelte-s6v612">window.plausible =
			window.plausible ||
			function () {
				;(window.plausible.q = window.plausible.q || []).push(arguments)
			}
	</script><!-- HEAD_svelte-kmiyj1_END --><!-- HEAD_svelte-1m45x84_START --><meta name="description" content="Get a real-time Novo Nordisk A/S (NVO) stock price quote with breaking news, financials, statistics, charts and more."><link rel="canonical" href="https://stockanalysis.com/stocks/nvo/"><meta property="og:title" content="Novo Nordisk A/S (NVO) Stock Price, Quote &amp; News - Stock Analysis"><meta property="og:description" content="Get a real-time Novo Nordisk A/S (NVO) stock price quote with breaking news, financials, statistics, charts and more."><meta property="og:url" content="https://stockanalysis.com/stocks/nvo/"><meta property="og:image" content="https://stockanalysis.com/img/bear-vs-bull.jpg"><meta property="og:type" content="website"><meta property="og:site_name" content="Stock Analysis"><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content="@stock_analysisx"><meta name="twitter:title" content="Novo Nordisk A/S (NVO) Stock Price, Quote &amp; News - Stock Analysis"><meta name="twitter:description" content="Get a real-time Novo Nordisk A/S (NVO) stock price quote with breaking news, financials, statistics, charts and more."><meta name="twitter:image" content="https://stockanalysis.com/img/bear-vs-bull.jpg"><!-- HEAD_svelte-1m45x84_END -->
		<link rel="shortcut icon" href="https://stockanalysis.com/favicon.ico">
		<link rel="icon" type="image/png" sizes="32x32" href="https://stockanalysis.com/favicon-32x32.png">
		<link rel="icon" type="image/png" sizes="16x16" href="https://stockanalysis.com/favicon-16x16.png">
		<link rel="apple-touch-icon" href="https://stockanalysis.com/apple-touch-icon.png" sizes="180x180">
	</head>
	<body data-sveltekit-preload-data="hover">
		<div>    <header class="sticky top-0 z-50 bg-white shadow-md dark:bg-dark-800 landscape:static landscape:lg:sticky"><div class="flex flex-row items-center gap-x-1 py-1.5 px-1 tiny:gap-x-1 tiny:px-2 xs:gap-x-3 xs:px-3 sm:py-2 lg:gap-x-4 xxl:px-4 xxxl:px-6"><a href="#main" class="sr-only focus:not-sr-only" data-svelte-h="svelte-18qvitj">Skip to main content</a>   <button class="xxl:hidden" aria-label="Open Menu" aria-controls="left-navigation" aria-expanded="false"><!-- HTML_TAG_START --><svg class="h-8 w-8 cursor-pointer text-faded" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg><!-- HTML_TAG_END --></button> <a aria-label="Stock Analysis home page" href="/"><div class="mx-1 h-8 overflow-hidden md:h-auto lg:mx-0 max-w-[32px] md:max-w-none"><!-- HTML_TAG_START --><svg viewBox="0 0 3060 928" class="h-8 overflow-hidden md:h-9" style="max-width:200px"><g transform="matrix(.1 0 0 -.1 0 928)"><path d="M4435 9024c-357-23-790-113-1155-240C1772 8261 655 6937 391 5361c-49-287-56-383-56-731s9-466 55-741C676 2195 1927 818 3588 371c427-115 782-157 1247-148 331 7 533 31 845 98 1004 218 1905 791 2547 1620 477 616 789 1386 882 2174 134 1129-190 2299-882 3194-606 782-1436 1334-2375 1576-409 106-632 136-1052 140-168 1-332 1-365-1zM2475 7196c18-8 39-25 47-38 11-19 14-325 18-1671l5-1648 798 703c439 387 813 711 832 721 59 32 29 54 592-415 145-120 265-218 269-218 8 0-6-13 744 685l634 590-73 3c-82 3-113 18-131 62-16 38-6 75 27 106 26 24 27 24 249 24h222l26-31 26-31v-440l-29-29c-38-37-88-39-128-5-26 23-28 30-33 120l-5 95-630-586c-852-792-840-781-869-789-14-3-36-4-49 0-12 3-197 149-411 325l-388 321-33-28c-18-15-396-346-839-737l-806-710V2240h170l2 615 3 615 28 27 27 28 283 3c155 2 297 0 316-3 18-3 44-17 57-30l24-24V2240h360v1055c0 1173-4 1112 65 1141 30 12 86 14 325 12 275-3 290-4 317-24 15-11 31-32 34-45 4-13 7-500 8-1081l1-1058h360v1779l24 28 24 28 303 3c216 2 311-1 331-9 60-25 58 14 58-949v-880h360v2508l26 31 26 31h635l27-26 26-27V2240h330c364 0 376-2 400-59 14-35 8-69-19-102l-19-24-2509-5c-1869-4-2516-2-2539 6-17 7-39 22-48 35-15 22-16 229-16 2527 0 2768-5 2548 63 2577 40 18 32 17 72 1z" fill="rgba(60, 116, 212)"></path><path d="M6210 3430V2240h360v2380h-360V3430zM4010 3245V2240h350v2010h-350V3245zM5110 3065v-825h360v1650h-360v-825zM2900 2785v-545h360v1090h-360v-545z" fill="rgba(60, 116, 212)"></path><path d="M12170 8059c-615-57-1007-330-1132-789-20-75-23-107-23-285s3-209 24-285c43-159 120-296 227-404 187-188 416-308 869-452 350-112 490-174 580-256 70-64 94-113 95-191 0-175-186-279-475-264-315 17-500 155-537 403-6 44-12 80-13 82-2 2-759-152-852-173-21-5-23-11-23-66 0-138 55-303 144-437 59-87 196-220 294-285 317-211 805-307 1281-251 599 69 965 367 1073 869 19 91 16 342-6 445-63 301-247 521-571 683-137 69-236 106-546 205-318 102-431 146-519 202-213 138-190 394 42 476 78 27 130 35 244 35 169 0 260-28 343-106 57-53 86-113 101-210 6-38 12-70 13-71s195 38 431 87 433 89 438 89c13 0 9 79-7 175-70 400-425 676-977 760-131 20-383 27-518 14zM20030 8054c-619-67-1071-358-1317-849-161-319-233-724-204-1138 48-676 310-1156 789-1446 363-219 933-290 1430-177 337 77 630 246 839 485 234 268 380 617 434 1036 19 143 16 502-4 650-81 586-347 1002-798 1244-312 168-750 241-1169 195zm345-734c192-22 316-79 435-199 158-159 241-401 258-748 23-460-64-814-249-1017-143-156-370-238-618-223-404 25-641 265-726 732-25 137-31 498-11 650 66 500 304 771 706 804 52 5 100 9 105 10 6 0 51-4 100-9zM24375 8059c-135-12-372-59-480-94-216-72-432-202-584-354-258-256-417-628-461-1073-16-167-8-544 15-693 68-436 222-763 480-1014 318-310 760-456 1325-438 195 7 312 22 471 62 417 106 726 366 869 732 45 114 86 272 73 283-7 7-790 230-806 230-4 0-7-22-7-49 0-122-79-279-183-364-62-51-193-111-292-133-108-25-349-25-450 0-408 100-582 476-562 1211 14 517 137 779 423 898 212 89 582 79 750-19 55-32 124-108 152-165 31-65 52-169 52-266 0-73 2-83 18-83 27 0 852 187 860 195 12 12 5 218-11 290-62 288-252 521-547 670-151 76-325 126-550 160-133 19-412 27-555 14zM14450 7385v-605h670v540h540V5080h-380v-610h1660v610h-380v2240h540v-540h670v1210h-3320v-605zM26880 7680v-310h390l-2-1142-3-1143-192-3-193-2v-610h1670v610h-390v790h247l48-77c26-43 221-358 433-700l386-623h1046v610h-365l-419 649c-231 357-420 651-420 654-1 3 197 226 438 496l439 491h297v620h-1520v-619l136-3 135-3-222-245c-122-135-264-291-316-347l-95-103h-248v700h330v620h-1610v-310zM25340 3474c-291-34-456-99-590-234-129-128-186-291-177-500 11-237 103-393 311-525 87-55 180-96 366-160 364-125 431-159 469-238 57-118-7-204-170-233-95-17-161-12-263 17-57 17-78 29-122 73-53 54-84 122-84 188 0 15-3 28-7 28-5 0-133-26-287-57l-278-58 5-75c20-289 296-520 697-585 122-19 369-20 478 0 276 48 470 178 566 378 59 123 71 179 70 317-1 185-44 305-151 420-115 125-237 188-583 300-352 115-419 159-428 278-5 76 21 116 103 157 54 27 69 30 160 30 123 0 186-20 239-74 36-37 66-108 66-157 0-20 4-23 28-18 15 3 142 29 282 58l255 52 3 38c5 56-15 135-54 216-79 166-264 287-519 340-87 19-314 32-385 24zM29275 3469c-284-32-507-151-619-332-66-107-87-180-93-323-9-208 41-357 161-479 124-125 228-180 571-300 281-98 309-111 367-163 66-60 83-122 51-189-24-52-78-82-174-99-245-43-447 66-466 252-3 30-9 54-12 54s-131-26-283-57l-278-57v-56c0-124 60-251 170-360 129-127 313-213 531-246 150-23 452-14 564 16 165 44 325 140 406 242 95 119 143 265 142 433 0 290-129 477-420 612-43 20-184 71-315 114-347 114-404 148-429 259-18 76 23 139 116 181 66 30 223 33 301 6 81-28 135-97 149-190 5-29 12-47 19-44 6 2 130 28 276 57s269 57 274 61c18 16-9 163-43 235-40 86-88 145-165 202-127 94-297 152-507 171-129 12-179 12-294 0zM11430 2503c-183-511-337-936-342-945-7-15-23-18-93-18h-85v-400h900v400h-103c-57 0-106 3-109 6s10 54 30 115l37 109 369-2 369-3 38-100c21-55 38-106 39-112 0-10-27-13-105-13h-105v-400l478 2 477 3 3 197 2 197-92 3-93 3-375 943-375 942h-531l-334-927zm704 13c64-181 116-333 116-337 0-11-450-12-450-1-2 20 206 680 211 674 4-4 59-155 123-336zM13690 3230v-200h250l-2-742-3-743-122-3-123-3v-399h1050v400h-120c-87 0-122 3-125 13-3 6-4 224-3 484l3 472 468-685 468-684 282 2 282 3 3 943 2 942h250v400h-1060v-400h250v-490c0-269-1-490-3-490-1 0-212 310-467 690l-465 689-407 1h-408v-200zM17555 3413c-3-10-130-362-282-783-151-421-301-837-332-925l-58-160-86-3-87-3v-399l448 2 447 3 3 198 2 197h-110c-60 0-110 3-110 7 0 5 16 56 36 115l36 108h736l28-72c14-40 33-88 40-107 8-18 14-37 14-42s-47-9-105-9h-105v-400h950v399l-87 3-88 3-375 940-376 940-266 3c-246 2-266 1-273-15zm379-902c64-184 115-336 113-338s-106-2-230-1l-225 3 89 290c49 160 96 314 105 343 9 30 19 50 23 45 5-4 60-158 125-342zM19490 3230v-200h250V1540h-260l2-198 3-197 933-3 932-2v790h-430v-350h-600v1450h250v400h-1080v-200zM21750 3230v-200h185l348-535 347-536-2-207-3-207-122-3-123-3v-399h1080v400h-250v425l329 530 329 530 96 3 96 3v399h-1000v-400h95c52 0 95-3 95-8 0-4-72-130-159-280l-159-273-167 267c-91 146-169 272-172 280-4 11 14 14 96 14h101v400h-1040v-200zM26880 3230v-200h250V1540h-250l2-198 3-197 538-3 537-2v399l-122 3-123 3-3 743-2 742h250v400h-1080v-200z"></path></g></svg><!-- HTML_TAG_END --></div></a> <div class="ml-0.5 max-w-screen-xsm grow md:ml-2 xxl:ml-6 xxxl:ml-12"><form action="/search/" method="get" role="search"><div class="relative flex items-center"><div class="absolute inset-y-0 left-0 flex items-center pl-2.5"><!-- HTML_TAG_START --><svg class="h-4 w-4 text-icon xs:h-5 xs:w-5" fill="none" stroke-linecap="round" stroke-linejoin="round" stroke-width="3" stroke="currentColor" viewBox="0 0 24 24" style="max-width: 40px" aria-hidden="true"><path d="M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"></path></svg><!-- HTML_TAG_END --></div> <input class="grow rounded-sm border border-default py-1.5 pl-7 text-sm placeholder-gray-700 dark:placeholder-gray-200 focus:border-default focus:shadow-lg focus:outline-none focus:ring-0 tiny:pl-8 xs:pl-10 xs:text-base md:py-2 w-full bg-gray-50 hover:bg-white focus:bg-white dark:bg-dark-700 dark:hover:bg-dark-700 dark:focus:bg-dark-700" type="text" aria-label="Search" role="combobox" aria-expanded="false" aria-controls="owned_listbox" autocomplete="off" spellcheck="false" aria-autocomplete="list" placeholder="Company or stock symbol..." name="q" value="">    </div></form></div>   <div class="ml-auto hidden space-x-2 xxl:flex"><a class="inline-flex w-full items-center justify-center whitespace-nowrap rounded-sm bg-white px-4 py-1.5 text-lg font-semibold text-default hover:bg-gray-50 focus:outline-none focus:ring-2 focus:ring-blue-500 dark:bg-dark-800 dark:text-default dark:hover:bg-dark-700" href="/login/" data-svelte-h="svelte-1kqtjev">Log In</a> <a class="inline-flex items-center justify-center whitespace-nowrap rounded-sm border border-transparent bg-blue-brand_light px-4 py-1.5 text-lg font-semibold text-white shadow-sm hover:bg-blue-brand_sharp focus:outline-none focus:ring-2 focus:ring-blue-500 dark:text-white" href="/pro/">Free Trial</a></div></div></header> <div class="grow xxl:grid-cols-leftnav xxl:grid"> <div class="z-40 border-r border-gray-100 bg-white dark:border-neutral-700 dark:bg-dark-800 hidden xxl:block"><div class="top-14 mt-1 overflow-y-auto overscroll-contain bg-white px-3 pb-4 pt-2 dark:bg-dark-800 xs:px-4 sm:px-3 xxl:sticky xxl:mt-0 xxl:px-5 xxl:py-4" id="left-navigation"><nav class="flex flex-col text-sm font-semibold"><div class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700"><a class="flex grow items-center py-1.5 px-2 xs:py-2 text-gray-600 dark:text-gray-300" href="/" title="Home"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M3 12l2-2m0 0l7-7 7 7M5 10v10a1 1 0 001 1h3m10-11l2 2m-2-2v10a1 1 0 01-1 1h-3m-6 0a1 1 0 001-1v-4a1 1 0 011-1h2a1 1 0 011 1v4a1 1 0 001 1m-6 0h6"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Home</span></a></div><div><div class="mt-1 flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700 bg-gray-100 dark:bg-dark-700"><a class="mr-1 flex grow items-center px-2 py-1.5 xs:py-2 text-gray-600 dark:text-gray-300 xxl:mr-0" href="/stocks/" title="Stocks"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Stocks</span></a> <button class="ml-auto cursor-pointer border-l border-gray-300 px-2 dark:border-dark-600 xxl:px-1" aria-controls="Stocks-menu" aria-expanded="true" aria-label="Expand Stocks menu"><svg class="h-5 w-5 text-gray-300 dark:text-dark-400 rotate-90 text-gray-400" viewBox="0 0 20 20" style="max-width: 20px"><path d="M6 6L14 10L6 14V6Z" fill="currentColor"></path></svg></button></div> <ul class="block pt-0.5" id="Stocks-menu"><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/stocks/screener/" title="Stock Screener">Stock Screener</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/stocks/earnings-calendar/" title="Earnings Calendar">Earnings Calendar</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/stocks/industry/" title="By Industry">By Industry</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/list/" title="Stock Lists">Stock Lists</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/analysts/" title="Top Analysts">Top Analysts</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/analysts/top-stocks/" title="Top Stocks">Top Stocks</a> </li></ul></div><div><div class="mt-1 flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700"><a class="mr-1 flex grow items-center px-2 py-1.5 xs:py-2 text-gray-600 dark:text-gray-300 xxl:mr-0" href="/ipos/" title="IPOs"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M8 7V3m8 4V3m-9 8h10M5 21h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v12a2 2 0 002 2z"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">IPOs</span></a> <button class="ml-auto cursor-pointer border-l border-gray-300 px-2 dark:border-dark-600 xxl:px-1" aria-controls="IPOs-menu" aria-expanded="false" aria-label="Expand IPOs menu"><svg class="h-5 w-5 text-gray-300 dark:text-dark-400" viewBox="0 0 20 20" style="max-width: 20px"><path d="M6 6L14 10L6 14V6Z" fill="currentColor"></path></svg></button></div> <ul class="hidden" id="IPOs-menu"><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/ipos/" title="Recent IPOs">Recent IPOs</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/ipos/calendar/" title="IPO Calendar">IPO Calendar</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/ipos/statistics/" title="IPO Statistics">IPO Statistics</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/ipos/news/" title="IPO News">IPO News</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/ipos/screener/" title="IPO Screener">IPO Screener</a> </li></ul></div><div><div class="mt-1 flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700"><a class="mr-1 flex grow items-center px-2 py-1.5 xs:py-2 text-gray-600 dark:text-gray-300 xxl:mr-0" href="/etf/" title="ETFs"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 11H5m14 0a2 2 0 012 2v6a2 2 0 01-2 2H5a2 2 0 01-2-2v-6a2 2 0 012-2m14 0V9a2 2 0 00-2-2M5 11V9a2 2 0 012-2m0 0V5a2 2 0 012-2h6a2 2 0 012 2v2M7 7h10"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">ETFs</span></a> <button class="ml-auto cursor-pointer border-l border-gray-300 px-2 dark:border-dark-600 xxl:px-1" aria-controls="ETFs-menu" aria-expanded="false" aria-label="Expand ETFs menu"><svg class="h-5 w-5 text-gray-300 dark:text-dark-400" viewBox="0 0 20 20" style="max-width: 20px"><path d="M6 6L14 10L6 14V6Z" fill="currentColor"></path></svg></button></div> <ul class="hidden" id="ETFs-menu"><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/etf/screener/" title="ETF Screener">ETF Screener</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/etf/compare/" title="Compare Tool">Compare Tool</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/etf/list/new/" title="New Launches">New Launches</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/etf/provider/" title="ETF Providers">ETF Providers</a> </li></ul></div><div class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700 mt-1"><a class="flex grow items-center py-1.5 px-2 xs:py-2 text-gray-600 dark:text-gray-300" href="/news/" title="News"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 20H5a2 2 0 01-2-2V6a2 2 0 012-2h10a2 2 0 012 2v1m2 13a2 2 0 01-2-2V7m2 13a2 2 0 002-2V9a2 2 0 00-2-2h-2m-4-3H9M7 16h6M7 8h6v4H7V8z"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">News</span></a></div><div class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700 mt-1"><a class="flex grow items-center py-1.5 px-2 xs:py-2 text-gray-600 dark:text-gray-300" href="/trending/" title="Trending"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 7h8m0 0v8m0-8l-8 8-4-4-6 6"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Trending</span></a></div><div><div class="mt-1 flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700"><a class="mr-1 flex grow items-center px-2 py-1.5 xs:py-2 text-gray-600 dark:text-gray-300 xxl:mr-0" href="/markets/gainers/" title="Market Movers"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M16 8v8m-4-5v5m-4-2v2m-2 4h12a2 2 0 002-2V6a2 2 0 00-2-2H6a2 2 0 00-2 2v12a2 2 0 002 2z"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Market Movers</span></a> <button class="ml-auto cursor-pointer border-l border-gray-300 px-2 dark:border-dark-600 xxl:px-1" aria-controls="Market Movers-menu" aria-expanded="false" aria-label="Expand Market Movers menu"><svg class="h-5 w-5 text-gray-300 dark:text-dark-400" viewBox="0 0 20 20" style="max-width: 20px"><path d="M6 6L14 10L6 14V6Z" fill="currentColor"></path></svg></button></div> <ul class="hidden" id="Market Movers-menu"><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/markets/gainers/" title="Top Gainers">Top Gainers</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/markets/losers/" title="Top Losers">Top Losers</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/markets/active/" title="Most Active">Most Active</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/markets/premarket/" title="Premarket">Premarket</a> </li><li><a class="block rounded-md py-1.5 pl-11 pr-2 text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700" href="/markets/afterhours/" title="After Hours">After Hours</a> </li></ul></div><div class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700 mt-1"><a class="flex grow items-center py-1.5 px-2 xs:py-2 text-gray-600 dark:text-gray-300" href="/actions/" title="Corporate Actions"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M5 8h14M5 8a2 2 0 110-4h14a2 2 0 110 4M5 8v10a2 2 0 002 2h10a2 2 0 002-2V8m-9 4h4"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Corporate Actions</span></a></div><div class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700 mt-1"><a class="flex grow items-center py-1.5 px-2 xs:py-2 text-gray-600 dark:text-gray-300" href="/subscribe/" title="Market Newsletter"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M21.75 6.75v10.5a2.25 2.25 0 01-2.25 2.25h-15a2.25 2.25 0 01-2.25-2.25V6.75m19.5 0A2.25 2.25 0 0019.5 4.5h-15a2.25 2.25 0 00-2.25 2.25m19.5 0v.243a2.25 2.25 0 01-1.07 1.916l-7.5 4.615a2.25 2.25 0 01-2.36 0L3.32 8.91a2.25 2.25 0 01-1.07-1.916V6.75"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Market Newsletter</span></a></div><div class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700"><a class="flex grow items-center py-1.5 px-2 xs:py-2 text-gray-600 dark:text-gray-300" href="/pro/" title="Stock Analysis Pro"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 7.5v3m0 0v3m0-3h3m-3 0h-3m-2.25-4.125a3.375 3.375 0 11-6.75 0 3.375 3.375 0 016.75 0zM4 19.235v-.11a6.375 6.375 0 0112.75 0v.109A12.318 12.318 0 0110.374 21c-2.331 0-4.512-.645-6.374-1.766z"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Stock Analysis Pro</span></a></div><div class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:hover:bg-neutral-700 mt-1"><a class="flex grow items-center py-1.5 px-2 xs:py-2 text-gray-600 dark:text-gray-300" href="/watchlist/" title="Watchlist"><!-- HTML_TAG_START --><svg class="h-5 w-5 xs:h-6 xs:w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 4v16m8-8H4"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Watchlist</span></a></div></nav> <div class="mt-4 hidden cursor-pointer items-center border-t border-default pt-1 xxl:flex"><button class="flex grow items-center rounded-md text-sm font-semibold text-gray-600 hover:bg-gray-50 hover:text-gray-900 dark:text-gray-300 hover:dark:bg-dark-700 xxl:p-2" title="Collapse Menu"><!-- HTML_TAG_START --><svg class="h-6 w-6 text-gray-500 dark:text-dark-400 xxl:h-5 xxl:w-5 xxxl:h-6 xxxl:w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M11 19l-7-7 7-7m8 14l-7-7 7-7"></path></svg><!-- HTML_TAG_END --> <span class="ml-3">Collapse</span></button></div></div> </div> <div> <main id="main" class="contain"><div class="mx-auto mb-2"><div class="mb-4 flex items-start justify-between"><div><h1 class="mb-0 text-2xl font-bold text-default sm:text-[26px]">Novo Nordisk A/S (NVO)</h1> <div class="mt-[1px] text-tiny text-faded">NYSE: NVO · IEX Real-Time Price · USD</div> </div> <div class="hidden md:flex"><button class="hidden md:inline-flex items-center gap-x-1.5 whitespace-nowrap rounded-md bg-blue-brand_sharp py-1.5 px-3 lg:px-2.5 text-base font-semibold text-white shadow-sm hover:bg-blue-500"><span class="hidden lg:inline" data-svelte-h="svelte-dpniqx">Add to </span>Watchlist
		<!-- HTML_TAG_START --><svg class="h-5 w-5 lg:-ml-0.5" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v6m3-3H9m12 0a9 9 0 11-18 0 9 9 0 0118 0z"></path></svg><!-- HTML_TAG_END --></button></div></div>  <div class="mb-5 flex flex-row items-end space-x-2 xs:space-x-3 bp:space-x-5"><div class="max-w-[50%]"> <div class="text-4xl font-bold block sm:inline">102.68</div>  <div class="font-semibold block text-lg xs:text-xl sm:inline sm:text-2xl text-red-vivid">-0.03 (-0.03%)</div>   <div class="mt-0.5 text-xxs text-faded xs:text-tiny bp:text-sm"><span class="block font-semibold sm:inline" data-svelte-h="svelte-77ql6t">At close:</span> Dec 26, 2023, 4:00 PM</div></div>  <div class="border-l border-default pl-3 bp:pl-5"><div class="block text-[1.7rem] font-semibold leading-5 text-faded sm:inline">102.84</div> <div class="mt-1.5 block text-sm xs:text-base sm:mt-0 sm:inline sm:text-lg text-green-vivid">+0.16 (0.16%)</div> <div class="mt-1 text-xxs text-faded xs:text-tiny sm:flex"><span class="flex items-center"><!-- HTML_TAG_START --><svg class="h-6 w-6 sm:h-4 sm:w-4 text-yellow-500" fill="none" viewBox="0 0 24 24" stroke="currentColor" style="max-width:40px"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 3v1m0 16v1m9-9h-1M4 12H3m15.364 6.364l-.707-.707M6.343 6.343l-.707-.707m12.728 0l-.707.707M6.343 17.657l-.707.707M16 12a4 4 0 11-8 0 4 4 0 018 0z"></path></svg><!-- HTML_TAG_END --> <span class="ml-0.5 whitespace-nowrap font-semibold md:ml-1">Pre-market:</span></span> <span class="sm:ml-1">Dec 27, 2023, 7:46 AM EST</span></div></div></div>  <nav class="w-full border-b-2 border-below-title dark:border-gray-500"><ul class="navmenu"><li><a href="/stocks/nvo/" data-title="Overview" class="active">Overview</a></li> <li><a href="/stocks/nvo/financials/" data-title="Financials">Financials</a></li> <li><a href="/stocks/nvo/statistics/" data-title="Statistics">Statistics</a></li> <li><a href="/stocks/nvo/forecast/" data-title="Forecast">Forecast</a></li> <li><a href="/stocks/nvo/dividend/" data-title="Dividends">Dividends</a></li> <li><a href="/stocks/nvo/company/" data-title="Profile">Profile</a></li> <li><a href="/stocks/nvo/chart/" data-title="Chart">Chart</a></li></ul></nav></div>  <div class="mt-4 lg:flex lg:flex-row lg:gap-x-4"><div class="order-3 grow overflow-hidden  border-t border-default py-0.5 xs:py-1 sm:px-0.5 sm:pb-3 sm:pt-2.5 lg:mb-0 lg:border-0 lg:border-l lg:border-sharp lg:px-0 lg:py-0 lg:pl-3 mb-4 border-b"><div class="flex items-center justify-between py-1 sm:pt-0.5"><div class="hide-scroll overflow-x-auto"><ul class="flex space-x-[3px] whitespace-nowrap pl-0.5 xs:space-x-1"><li><button class="rounded-md py-1 px-1 text-smaller xs:px-[3px] bp:px-1.5 sm:px-2 xxxl:px-3 font-semibold text-light dark:bg-dark-700 bp:bg-gray-50"><span class="block sm:hidden lg:block xl:hidden" data-svelte-h="svelte-binset">1D</span> <span class="hidden sm:block lg:hidden xl:block" data-svelte-h="svelte-9dflnz">1 Day</span></button></li> <li><button class="rounded-md py-1 px-1 text-smaller xs:px-[3px] bp:px-1.5 sm:px-2 xxxl:px-3 text-default hover:bg-gray-50 hover:dark:bg-dark-700"><span class="block sm:hidden lg:block xl:hidden" data-svelte-h="svelte-z3649l">5D</span> <span class="hidden sm:block lg:hidden xl:block" data-svelte-h="svelte-h1126o">5 Days</span></button></li> <li><button class="rounded-md py-1 px-1 text-smaller xs:px-[3px] bp:px-1.5 sm:px-2 xxxl:px-3 text-default hover:bg-gray-50 hover:dark:bg-dark-700"><span class="block sm:hidden lg:block xl:hidden" data-svelte-h="svelte-kfgaok">1M</span> <span class="hidden sm:block lg:hidden xl:block" data-svelte-h="svelte-5zmjub">1 Month</span></button></li> <li><button class="rounded-md py-1 px-1 text-smaller xs:px-[3px] bp:px-1.5 sm:px-2 xxxl:px-3 text-default hover:bg-gray-50 hover:dark:bg-dark-700">YTD</button></li> <li><button class="rounded-md py-1 px-1 text-smaller xs:px-[3px] bp:px-1.5 sm:px-2 xxxl:px-3 text-default hover:bg-gray-50 hover:dark:bg-dark-700"><span class="block sm:hidden lg:block xl:hidden" data-svelte-h="svelte-mgxkxs">1Y</span> <span class="hidden sm:block lg:hidden xl:block" data-svelte-h="svelte-18eelfe">1 Year</span></button></li> <li><button class="rounded-md py-1 px-1 text-smaller xs:px-[3px] bp:px-1.5 sm:px-2 xxxl:px-3 text-default hover:bg-gray-50 hover:dark:bg-dark-700"><span class="block sm:hidden lg:block xl:hidden" data-svelte-h="svelte-1dso4hw">5Y</span> <span class="hidden sm:block lg:hidden xl:block" data-svelte-h="svelte-1cfvdkf">5 Years</span></button></li> <li><button class="rounded-md py-1 px-1 text-smaller xs:px-[3px] bp:px-1.5 sm:px-2 xxxl:px-3 text-default hover:bg-gray-50 hover:dark:bg-dark-700">Max</button></li></ul></div> <div class="flex shrink flex-row space-x-1 pr-1 text-smaller sm:text-base"><span class="text-red-vivid">-0.03%</span> <span class="hidden text-faded sm:block">(1D)</span></div></div> <div class="h-[250px] sm:h-[300px]"></div></div>  <div class="order-1 flex flex-row space-x-2 tiny:space-x-3 xs:space-x-4"><table class="w-[48%] text-sm text-gray-900 dark:text-dark-200 tiny:text-small lg:w-auto lg:min-w-[210px]" data-test="overview-info"><tbody><tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2"><a href="/stocks/nvo/market-cap/" class="dothref text-gray-900 dark:text-dark-200">Market Cap</a></td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">459.76B</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2"><a href="/stocks/nvo/revenue/" class="dothref text-gray-900 dark:text-dark-200">Revenue (ttm)</a></td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">30.42B</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2">Net Income (ttm)</td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">10.68B</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2">Shares Out <span class="relative" role="tooltip"><span class="absolute -right-[13px] -top-[3px] cursor-pointer p-1 text-gray-300 hover:text-gray-600 dark:text-dark-400 dark:hover:text-dark-300"><!-- HTML_TAG_START --><svg class="h-[9px] w-[9px]" viewBox="0 0 4 16" fill="currentColor" style="max-width:20px"><path d="M0 6h4v10h-4v-10zm2-6c1.1 0 2 .9 2 2s-.9 2-2 2-2-.9-2-2 .9-2 2-2z"></path></svg><!-- HTML_TAG_END --></span></span> </td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">4.48B</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2">EPS (ttm)</td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">2.48</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2" data-svelte-h="svelte-1nsbsre">PE Ratio</td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">41.63</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2" data-svelte-h="svelte-1bdxt6">Forward PE</td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">31.15</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2"><a href="/stocks/nvo/dividend/" class="dothref text-gray-900 dark:text-dark-200">Dividend</a></td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">$0.74 (0.72%)</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap px-0.5 py-[1px] xs:px-1 sm:py-2" data-svelte-h="svelte-1ncihu7">Ex-Dividend Date</td> <td class="whitespace-nowrap px-0.5 py-[1px] text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">Aug 18, 2023</td></tr></tbody></table> <table class="w-[48%] text-sm text-gray-900 dark:text-dark-200 tiny:text-small lg:w-auto lg:min-w-[210px]" data-test="overview-quote"><tbody><tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-1u6woti">Volume</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">1,841,225</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-17lhbqk">Open</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">102.56</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2">Previous Close</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">102.71</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-nkp41s">Day's Range</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">102.41 - 103.13</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-1v0rtkh">52-Week Range</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">65.05 - 105.69</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-1c8cr46">Beta</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">0.19</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-1rkp30v">Analysts</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">Strong Buy</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-1u8go0m">Price Target</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">90.13 (-12.22%)</td></tr> <tr class="flex flex-col border-b border-default py-1 sm:table-row sm:py-0"><td class="whitespace-nowrap py-[1px] px-0.5 xs:px-1 sm:py-2" data-svelte-h="svelte-7bvrkb">Earnings Date</td> <td class="whitespace-nowrap py-[1px] px-0.5 text-left text-smaller font-semibold tiny:text-base xs:px-1 sm:py-2 sm:text-right sm:text-small">Jan 31, 2024</td></tr></tbody></table></div></div> <div class="mt-6 lg:grid lg:grid-cols-sidebar_wide lg:gap-x-10"><div class="space-y-6 lg:order-2 lg:pt-1"><div class="px-0.5 lg:px-0"><h2 class="mb-2" data-test="overview-profile-header">About NVO</h2> <p data-test="overview-profile-description">Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and h... <a href="/stocks/nvo/company/" title="View company profile" tabindex="-1">[Read more]</a></p> <div class="mt-3 grid grid-cols-2 gap-3" data-test="overview-profile-values"><div class="col-span-1"><span class="block font-semibold">Industry</span> <a href="/stocks/industry/biotechnology/" class="dothref text-default">Biotechnology</a> </div><div class="col-span-1"><span class="block font-semibold">Sector</span> <a href="/stocks/sector/healthcare/" class="dothref text-default">Healthcare</a> </div><div class="col-span-1"><span class="block font-semibold">Founded</span> <span>1923</span> </div><div class="col-span-1"><span class="block font-semibold">Employees</span> <a href="/stocks/nvo/employees/" class="dothref text-default">55,185</a> </div><div class="col-span-1"><span class="block font-semibold">Stock Exchange</span> <span>NYSE</span> </div><div class="col-span-1"><span class="block font-semibold">Ticker Symbol</span> <span>NVO</span> </div></div> <a href="/stocks/nvo/company/" class="button mt-4 w-full">Full Company Profile</a></div> <div><h2 data-svelte-h="svelte-11uexdp">Financial Performance</h2> <p data-test="overview-performance-intro" class="mb-3">In 2022, Novo Nordisk's revenue was 176.95 billion, an increase of 25.68% compared to the previous year's 140.80 billion. Earnings were 55.53 billion, an increase of 16.27%.</p> <div class="undefined"></div> <span class="text-sm text-faded">Financial numbers in DKK</span> <a href="/stocks/nvo/financials/" class="button mt-4 w-full">Financial Statements</a></div> <div><h2 class="mb-2" data-svelte-h="svelte-avjv7o">Analyst Forecast</h2> <p class="mb-4" data-test="overview-forecast-intro">According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $90.13, which is a decrease of -12.22% from the latest price.</p> <div data-test="overview-forecast-targetchart" class="border border-default p-2 xs:p-3"><div class="m-auto mb-2 text-center text-xl font-semibold text-default" data-svelte-h="svelte-5xi68b">Price Target</div> <div class="mb-0.5 text-center text-4xl font-semibold text-red-vivid">$90.13</div> <div class="mb-1.5 text-center text-xl">(-12.22% downside)</div> <div class="py-1 text-center text-lg font-semibold text-default">Analyst Consensus: <span class="font-bold text-green-default">Strong Buy</span></div> <div class="undefined"></div></div> <a href="/stocks/nvo/forecast/" class="button mt-4 w-full">Stock Forecasts</a></div> <div class="lg:sticky lg:top-20"></div></div> <div class="uncontain lg:order-1"><div class="mt-6 lg:mt-0"><h2 class="mb-0 px-3 xs:px-4 sm:px-0" data-svelte-h="svelte-wzf0xf">News</h2> <div class="px-3 xs:px-4 sm:px-0"><div class="flex flex-row items-center justify-between overflow-x-auto border-b border-default py-1.5 md:py-0"><ul class="noshift hide-scroll mb-0.5 flex flex-row overflow-x-auto whitespace-nowrap text-smaller xs:space-x-1 xs:text-base"><li><button class="rounded-md px-2 py-0.5 xs:px-2.5 bp:px-3 sm:py-1 cursor-default bg-gray-50 font-semibold text-default dark:bg-dark-700">All</button></li> <li><button class="rounded-md px-2 py-0.5 xs:px-2.5 bp:px-3 sm:py-1 text-faded hover:bg-gray-50 hover:text-default hover:dark:bg-dark-700">Videos</button></li> <li><button class="rounded-md px-2 py-0.5 xs:px-2.5 bp:px-3 sm:py-1 text-faded hover:bg-gray-50 hover:text-default hover:dark:bg-dark-700"><span class="inline sm:hidden" data-svelte-h="svelte-jcsduj">Press</span><span class="hidden sm:inline" data-svelte-h="svelte-1y9dqbd">Press Releases</span></button></li> <li><button class="rounded-md px-2 py-0.5 xs:px-2.5 bp:px-3 sm:py-1 text-faded hover:bg-gray-50 hover:text-default hover:dark:bg-dark-700">Conversation</button></li></ul> <div class="relative mb-1 mr-px mt-px hidden max-w-[48%] sm:block sm:max-w-[170px]"><input class="controls-input w-full sm:py-2 dark:bg-dark-700" type="text" placeholder="Search news..." value=""> <div class="absolute inset-y-0 right-0 flex items-center pr-3"><!-- HTML_TAG_START --><svg class="h-4 w-4 xs:h-5 xs:w-5 text-gray-400" fill="none" stroke-linecap="round" stroke-linejoin="round" stroke-width="3" stroke="currentColor" viewBox="0 0 24 24" style="max-width: 40px" aria-hidden="true"><path d="M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"></path></svg><!-- HTML_TAG_END --></div></div></div></div>  <div class="mb-2 flex flex-col space-y-3 overflow-x-hidden bg-gray-200 dark:bg-dark-950 sm:space-y-0 sm:bg-white dark:sm:bg-dark-800 lg:border-0"><div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.marketwatch.com/story/novo-nordisk-fda-warn-of-fake-ozempic-6dca2448" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/w/4/im-31318914size1777777777777778width800-2206812.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.marketwatch.com/story/novo-nordisk-fda-warn-of-fake-ozempic-6dca2448" target="_blank" rel="nofollow noopener noreferrer">Novo Nordisk, FDA warn of fake Ozempic</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">The U.S. Food and Drug Administration has seized thousands of units of fake Ozempic, the agency said Thursday, warning that some counterfeit units of the Novo Nordisk NVO, -0.15% diabetes drug may sti...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 22, 2023, 1:01 PM EST">4 days ago - Market Watch</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.globenewswire.com/news-release/2023/12/22/2800529/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/s/v/press8-2206141.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.globenewswire.com/news-release/2023/12/22/2800529/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html" target="_blank" rel="nofollow noopener noreferrer">Novo Nordisk A/S - share repurchase programme</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Bagsværd, Denmark, 22 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 22, 2023, 6:52 AM EST">5 days ago - GlobeNewsWire</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://reut.rs/3tjXmwV" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/l/6/l6u7quzijbn5lihsxvjm7cf56i-2100374-2206150.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://reut.rs/3tjXmwV" target="_blank" rel="nofollow noopener noreferrer">US FDA warns about counterfeit versions of Novo's diabetes drug Ozempic</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">The U.S. Food and Drug Administration on Thursday warned consumers not to use counterfeit versions of Novo Nordisk's diabetes drug Ozempic that have been found in the country's drug supply chain.</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 22, 2023, 3:00 AM EST">5 days ago - Reuters</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.marketwatch.com/story/five-obesity-drug-trends-to-watch-in-2024-who-can-compete-with-eli-lilly-and-novo-nordisk-1dc62a7d" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/b/n/im-80508866size1777777777777778width800-2203823.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.marketwatch.com/story/five-obesity-drug-trends-to-watch-in-2024-who-can-compete-with-eli-lilly-and-novo-nordisk-1dc62a7d" target="_blank" rel="nofollow noopener noreferrer">Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a><a href="/stocks/alt/" class="ticker">ALT</a><a href="/stocks/amgn/" class="ticker">AMGN</a><a href="/stocks/gpcr/" class="ticker">GPCR</a><a href="/stocks/rhhby/" class="ticker">RHHBY</a><a href="/stocks/vktx/" class="ticker">VKTX</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 20, 2023, 11:17 AM EST">6 days ago - Market Watch</div></div></div> <div class="flex flex-col border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none dark:border-dark-600 dark:bg-dark-800 sm:border-b sm:py-6 sm:px-0 sm:shadow-none sm:first:pt-4 sm:last:border-b-0"><h3 class="mb-2.5 text-xl font-bold leading-snug xs:mb-3 sm:order-2 sm:leading-tight">Weight-loss drugs poised for big 2024 as demand surges</h3> <div class="mb-3 sm:order-3 lg:pr-2"> <div class="group relative block cursor-pointer bg-black bg-cover bg-[center_50%] object-contain after:block after:pb-[56.25%] after:content-[''] rounded-sm focus:outline-none focus:ring-2 focus:ring-blue-brand_light focus:ring-offset-2" data-title="Weight-loss drugs poised for big 2024 as demand surges" style="background-color: #eee;" tabindex="0"><div class="absolute top-[50%] left-[50%] z-10 h-[46px] w-[70px] -translate-x-1/2 -translate-y-1/2 rounded-lg bg-[#212121] opacity-80 transition-all before:absolute before:top-[50%] before:left-[50%] before:-translate-x-1/2 before:-translate-y-1/2 before:border-y-[11px] before:border-r-0 before:border-l-[19px] before:border-transparent before:border-l-white before:content-[''] group-hover:bg-[#ff0000] group-hover:opacity-100"></div> </div></div> <p class="overflow-auto text-[0.95rem] text-light sm:order-4">CNBC's Karen Gilchrist reviews the growth of the weight-loss drug industry and its outlook for 2024.</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 20, 2023, 8:25 AM EST">6 days ago - CNBC International TV</div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.reuters.com/breakingviews/ozempic-overshoot-will-plump-up-bargain-hunters-2023-12-18/" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/e/s/esws-2200631.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.reuters.com/breakingviews/ozempic-overshoot-will-plump-up-bargain-hunters-2023-12-18/" target="_blank" rel="nofollow noopener noreferrer">Ozempic overshoot will plump up bargain-hunters</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Weight-loss drug excitement went overboard in 2023. Novo Nordisk's Wegovy – which is known as Ozempic when used to treat diabetes – and Eli Lilly's Zepbound are the first effective treatments for obes...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 18, 2023, 11:01 AM EST">8 days ago - Reuters</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.forbes.com/sites/roberthart/2023/12/18/fake-wegovy-pharma-giant-novo-nordisk-reportedly-steps-up-efforts-tackling-illegal-weight-loss-drugs-sold-online/" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/f/6/fake-wegovy-pharma-giant-novo-nordisk-reportedly-steps-up-efforts-tackling-illegal-weight-loss-drugs-sold-online-2199900.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.forbes.com/sites/roberthart/2023/12/18/fake-wegovy-pharma-giant-novo-nordisk-reportedly-steps-up-efforts-tackling-illegal-weight-loss-drugs-sold-online/" target="_blank" rel="nofollow noopener noreferrer">Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity and ...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 18, 2023, 8:02 AM EST">9 days ago - Forbes</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-owner-commits-265-mln-wegovy-windfall-respiratory-diseases-2023-12-18/" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/f/r/fre21we-2200044.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-owner-commits-265-mln-wegovy-windfall-respiratory-diseases-2023-12-18/" target="_blank" rel="nofollow noopener noreferrer">Novo owner commits $265 mln of Wegovy windfall to respiratory diseases</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">The Novo Nordisk Foundation, which controls drug maker Novo Nordisk, said on Monday it would commit up to 1.8 billion Danish crowns ($265 million) to setting up an initiative aimed at improving vaccin...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 18, 2023, 2:03 AM EST">9 days ago - Reuters</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.reuters.com/business/healthcare-pharmaceuticals/indiamart-is-working-with-novo-nordisk-halt-illegal-wegovy-sales-source-2023-12-18/" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/f/e/few2-2199419.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.reuters.com/business/healthcare-pharmaceuticals/indiamart-is-working-with-novo-nordisk-halt-illegal-wegovy-sales-source-2023-12-18/" target="_blank" rel="nofollow noopener noreferrer">Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -source</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Indian online marketplace IndiaMART has been removing unauthorized listings of Novo Nordisk's blockbuster weight-loss drug Wegovy after holding talks with the Danish drugmaker in early October, a sour...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 17, 2023, 8:39 PM EST">9 days ago - Reuters</div></div></div> <div class="flex flex-col border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none dark:border-dark-600 dark:bg-dark-800 sm:border-b sm:py-6 sm:px-0 sm:shadow-none sm:first:pt-4 sm:last:border-b-0"><h3 class="mb-2.5 text-xl font-bold leading-snug xs:mb-3 sm:order-2 sm:leading-tight">Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year</h3> <div class="mb-3 sm:order-3 lg:pr-2"> <div class="group relative block cursor-pointer bg-black bg-cover bg-[center_50%] object-contain after:block after:pb-[56.25%] after:content-[''] rounded-sm focus:outline-none focus:ring-2 focus:ring-blue-brand_light focus:ring-offset-2" data-title="Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year" style="background-color: #eee;" tabindex="0"><div class="absolute top-[50%] left-[50%] z-10 h-[46px] w-[70px] -translate-x-1/2 -translate-y-1/2 rounded-lg bg-[#212121] opacity-80 transition-all before:absolute before:top-[50%] before:left-[50%] before:-translate-x-1/2 before:-translate-y-1/2 before:border-y-[11px] before:border-r-0 before:border-l-[19px] before:border-transparent before:border-l-white before:content-[''] group-hover:bg-[#ff0000] group-hover:opacity-100"></div> </div></div> <p class="overflow-auto text-[0.95rem] text-light sm:order-4">Novo Nordisk (NVO) and more specifically its weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street. The company's financial performance, impact and buzz has...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 17, 2023, 10:00 AM EST">9 days ago - Yahoo Finance</div></div> <div class="flex flex-col border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none dark:border-dark-600 dark:bg-dark-800 sm:border-b sm:py-6 sm:px-0 sm:shadow-none sm:first:pt-4 sm:last:border-b-0"><h3 class="mb-2.5 text-xl font-bold leading-snug xs:mb-3 sm:order-2 sm:leading-tight">Novo Nordisk: Everything investors need to know</h3> <div class="mb-3 sm:order-3 lg:pr-2"> <div class="group relative block cursor-pointer bg-black bg-cover bg-[center_50%] object-contain after:block after:pb-[56.25%] after:content-[''] rounded-sm focus:outline-none focus:ring-2 focus:ring-blue-brand_light focus:ring-offset-2" data-title="Novo Nordisk: Everything investors need to know" style="background-color: #eee;" tabindex="0"><div class="absolute top-[50%] left-[50%] z-10 h-[46px] w-[70px] -translate-x-1/2 -translate-y-1/2 rounded-lg bg-[#212121] opacity-80 transition-all before:absolute before:top-[50%] before:left-[50%] before:-translate-x-1/2 before:-translate-y-1/2 before:border-y-[11px] before:border-r-0 before:border-l-[19px] before:border-transparent before:border-l-white before:content-[''] group-hover:bg-[#ff0000] group-hover:opacity-100"></div> </div></div> <p class="overflow-auto text-[0.95rem] text-light sm:order-4">Yahoo Finance selected pharmaceutical firm Novo Nordisk (NVO) as it's 2023 Company of the Year. Developer of obesity medications Wegovy and Ozempic, Novo Nordisk stock has gained over 40% year-to-date...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 11, 2023, 4:47 PM EST">15 days ago - Yahoo Finance</div></div> <div class="flex flex-col border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none dark:border-dark-600 dark:bg-dark-800 sm:border-b sm:py-6 sm:px-0 sm:shadow-none sm:first:pt-4 sm:last:border-b-0"><h3 class="mb-2.5 text-xl font-bold leading-snug xs:mb-3 sm:order-2 sm:leading-tight">Novo Nordisk: Yahoo Finance's Company of the Year, 2023</h3> <div class="mb-3 sm:order-3 lg:pr-2"> <div class="group relative block cursor-pointer bg-black bg-cover bg-[center_50%] object-contain after:block after:pb-[56.25%] after:content-[''] rounded-sm focus:outline-none focus:ring-2 focus:ring-blue-brand_light focus:ring-offset-2" data-title="Novo Nordisk: Yahoo Finance's Company of the Year, 2023" style="background-color: #eee;" tabindex="0"><div class="absolute top-[50%] left-[50%] z-10 h-[46px] w-[70px] -translate-x-1/2 -translate-y-1/2 rounded-lg bg-[#212121] opacity-80 transition-all before:absolute before:top-[50%] before:left-[50%] before:-translate-x-1/2 before:-translate-y-1/2 before:border-y-[11px] before:border-r-0 before:border-l-[19px] before:border-transparent before:border-l-white before:content-[''] group-hover:bg-[#ff0000] group-hover:opacity-100"></div> </div></div> <p class="overflow-auto text-[0.95rem] text-light sm:order-4">Novo Nordisk (NVO) and more specifically its blockbuster weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street and well beyond this year, due to the company...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 11, 2023, 2:28 PM EST">15 days ago - Yahoo Finance</div></div> <div class="flex flex-col border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none dark:border-dark-600 dark:bg-dark-800 sm:border-b sm:py-6 sm:px-0 sm:shadow-none sm:first:pt-4 sm:last:border-b-0"><h3 class="mb-2.5 text-xl font-bold leading-snug xs:mb-3 sm:order-2 sm:leading-tight">Why Novo Nordisk's corporate structure stands out</h3> <div class="mb-3 sm:order-3 lg:pr-2"> <div class="group relative block cursor-pointer bg-black bg-cover bg-[center_50%] object-contain after:block after:pb-[56.25%] after:content-[''] rounded-sm focus:outline-none focus:ring-2 focus:ring-blue-brand_light focus:ring-offset-2" data-title="Why Novo Nordisk's corporate structure stands out" style="background-color: #eee;" tabindex="0"><div class="absolute top-[50%] left-[50%] z-10 h-[46px] w-[70px] -translate-x-1/2 -translate-y-1/2 rounded-lg bg-[#212121] opacity-80 transition-all before:absolute before:top-[50%] before:left-[50%] before:-translate-x-1/2 before:-translate-y-1/2 before:border-y-[11px] before:border-r-0 before:border-l-[19px] before:border-transparent before:border-l-white before:content-[''] group-hover:bg-[#ff0000] group-hover:opacity-100"></div> </div></div> <p class="overflow-auto text-[0.95rem] text-light sm:order-4">Yahoo Finance selected Novo Nordisk (NVO) as its Company of the Year for 2023, and there are plenty of reasons why. One interesting reason some investors may not know about, however, is its unique cor...</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 11, 2023, 1:34 PM EST">15 days ago - Yahoo Finance</div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-rivals-explore-booming-weight-loss-drug-market-entry-2023-12-08/" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/k/9/sm4nxzj3knluvfgclyvi3x4sgu-2189252.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-rivals-explore-booming-weight-loss-drug-market-entry-2023-12-08/" target="_blank" rel="nofollow noopener noreferrer">Novo, Lilly rivals explore booming weight-loss drug market entry</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up thr...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 8, 2023, 9:58 AM EST">18 days ago - Reuters</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.marketwatch.com/story/goldman-sachs-money-manager-digs-into-three-themes-for-long-term-growth-66add895" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/3/h/im-60177213size1777777777777778width800-2184207.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.marketwatch.com/story/goldman-sachs-money-manager-digs-into-three-themes-for-long-term-growth-66add895" target="_blank" rel="nofollow noopener noreferrer">Goldman Sachs money manager digs into three themes for long-term growth</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/axnx/" class="ticker">AXNX</a><a href="/stocks/cava/" class="ticker">CAVA</a><a href="/etf/gsc/" class="ticker">GSC</a><a href="/stocks/irtc/" class="ticker">IRTC</a><a href="/stocks/mth/" class="ticker">MTH</a><a href="/stocks/sg/" class="ticker">SG</a><a href="/stocks/shak/" class="ticker">SHAK</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 5, 2023, 11:27 AM EST">21 days ago - Market Watch</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.marketwatch.com/story/no-more-exercising-president-rfk-jr-heres-one-banks-outrageous-predictions-for-2024-1bc90579" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/i/v/im-23070502size1777777777777778width800-2183145.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.marketwatch.com/story/no-more-exercising-president-rfk-jr-heres-one-banks-outrageous-predictions-for-2024-1bc90579" target="_blank" rel="nofollow noopener noreferrer">No more exercising? President RFK Jr.? Here's one bank's outrageous predictions for 2024</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels will ge...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 5, 2023, 5:45 AM EST">22 days ago - Market Watch</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.marketbeat.com/originals/ozempic-vs-mounjaro-battle-of-the-bulge/?utm_source=snapi" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/t/s/med-20231204090609-battle-of-the-bulge-ozempic-vs-2182095.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.marketbeat.com/originals/ozempic-vs-mounjaro-battle-of-the-bulge/?utm_source=snapi" target="_blank" rel="nofollow noopener noreferrer">Ozempic vs. Mounjaro:: Battle of the bulge</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Nov...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 4, 2023, 10:16 AM EST">22 days ago - MarketBeat</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.barrons.com/articles/roche-stock-weight-loss-eli-lilly-novo-nordisk-f5fe020f" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/w/x/drugs18-2181671.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.barrons.com/articles/roche-stock-weight-loss-eli-lilly-novo-nordisk-f5fe020f" target="_blank" rel="nofollow noopener noreferrer">Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a><a href="/stocks/rhhby/" class="ticker">RHHBY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 4, 2023, 7:43 AM EST">23 days ago - Barrons</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.marketwatch.com/story/roche-strikes-3-1-billion-deal-to-buy-obesity-drug-maker-carmot-therapeutics-billion-in-race-to-rival-novo-nordisks-ozempic-6b88b8c9" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/a/e/im-740245size1777777777777778width800-2181363.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.marketwatch.com/story/roche-strikes-3-1-billion-deal-to-buy-obesity-drug-maker-carmot-therapeutics-billion-in-race-to-rival-novo-nordisks-ozempic-6b88b8c9" target="_blank" rel="nofollow noopener noreferrer">Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen No...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/rhhby/" class="ticker">RHHBY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 4, 2023, 5:40 AM EST">23 days ago - Market Watch</div></div></div> <div class="flex flex-col border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none dark:border-dark-600 dark:bg-dark-800 sm:border-b sm:py-6 sm:px-0 sm:shadow-none sm:first:pt-4 sm:last:border-b-0"><h3 class="mb-2.5 text-xl font-bold leading-snug xs:mb-3 sm:order-2 sm:leading-tight">There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen</h3> <div class="mb-3 sm:order-3 lg:pr-2"> <div class="group relative block cursor-pointer bg-black bg-cover bg-[center_50%] object-contain after:block after:pb-[56.25%] after:content-[''] rounded-sm focus:outline-none focus:ring-2 focus:ring-blue-brand_light focus:ring-offset-2" data-title="There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen" style="background-color: #eee;" tabindex="0"><div class="absolute top-[50%] left-[50%] z-10 h-[46px] w-[70px] -translate-x-1/2 -translate-y-1/2 rounded-lg bg-[#212121] opacity-80 transition-all before:absolute before:top-[50%] before:left-[50%] before:-translate-x-1/2 before:-translate-y-1/2 before:border-y-[11px] before:border-r-0 before:border-l-[19px] before:border-transparent before:border-l-white before:content-[''] group-hover:bg-[#ff0000] group-hover:opacity-100"></div> </div></div> <p class="overflow-auto text-[0.95rem] text-light sm:order-4">Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, an...</p> <div class="mt-1.5 sm:order-5 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 1, 2023, 12:22 PM EST">25 days ago - CNBC Television</div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://invezz.com/news/2023/12/01/eli-lilly-novo-nordisk-to-benefit-as-pfizers-weight-loss-drug-implodes/?utm_source=snapi" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/k/m/pfizer-stock-is-up-about-2-today-2179590.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://invezz.com/news/2023/12/01/eli-lilly-novo-nordisk-to-benefit-as-pfizers-weight-loss-drug-implodes/?utm_source=snapi" target="_blank" rel="nofollow noopener noreferrer">Eli Lilly, Novo Nordisk to benefit as Pfizer's weight loss drug implodes</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Eli Lilly (NYSE: LLY) and Novo Nordisk NYSE: NVO) stock prices have been some of the hottest names in Wall Street. NVO has soared by over 48% this year while LLY has surged by over 61%.</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a><a href="/stocks/pfe/" class="ticker">PFE</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 1, 2023, 7:58 AM EST">26 days ago - Invezz</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.reuters.com/world/maker-wegovy-ozempic-showers-money-us-obesity-doctors-2023-12-01/" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/a/x/ax5cpy2prfgongj4s5jaz2tmha-2179500.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.reuters.com/world/maker-wegovy-ozempic-showers-money-us-obesity-doctors-2023-12-01/" target="_blank" rel="nofollow noopener noreferrer">Maker of Wegovy, Ozempic showers money on U.S. obesity doctors</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found.</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 1, 2023, 6:11 AM EST">26 days ago - Reuters</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.barrons.com/articles/weight-loss-stocks-are-getting-pricey-here-are-some-alternatives-b867d642" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/b/a/bank41-2179543.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.barrons.com/articles/weight-loss-stocks-are-getting-pricey-here-are-some-alternatives-b867d642" target="_blank" rel="nofollow noopener noreferrer">Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to ...</p> <div class="mt-1.5 inline text-light sm:order-4 sm:mt-1"><span>Other symbols:</span> <a href="/stocks/lly/" class="ticker">LLY</a></div> <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Dec 1, 2023, 4:30 AM EST">26 days ago - Barrons</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.cnbc.com/2023/11/30/novo-nordisk-sues-pharmacies-over-impure-wegovy-ozempic-dupes.html" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/3/u/107295103-16935843032023-09-01t154153z-1005718174-rc2yy2ao8b7p-rtrmadp-0-novo-nordisk-lvmh-valuation-2178994.jpeg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.cnbc.com/2023/11/30/novo-nordisk-sues-pharmacies-over-impure-wegovy-ozempic-dupes.html" target="_blank" rel="nofollow noopener noreferrer">Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">The lawsuits come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in the U.S. due to skyrocketing demand.</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Nov 30, 2023, 4:57 PM EST">26 days ago - CNBC</div></div></div> <div class="gap-4 border-gray-300 bg-white p-4 shadow last:pb-1 last:shadow-none sm:border-b sm:px-0 sm:shadow-none sm:last:border-b-0 lg:gap-5 dark:border-dark-600 dark:bg-dark-800 sm:grid sm:grid-cols-news sm:py-6"><a class="sm:mt-1" href="https://www.forbes.com/sites/tylerroush/2023/11/30/novo-nordisk-sues-two-florida-pharmacies-for-allegedly-selling-impure-weight-loss-drugs/" target="_blank" rel="nofollow noopener noreferrer" aria-hidden="true" tabindex="-1"><img class="rounded" src="https://cdn.snapi.dev/images/v1/f/a/novo-nordisk-sues-two-florida-pharmacies-for-allegedly-selling-impure-weight-loss-drugs-2178014.jpg" alt="" loading="lazy" width="640" height="360"></a> <div class="flex flex-col"><h3 class="mb-2 mt-3 text-xl font-bold leading-snug sm:order-2 sm:mt-0 sm:leading-tight"><a class="dark:text-neutral-150 text-default hover:text-blue-brand_sharp dark:hover:text-blue-darklink" href="https://www.forbes.com/sites/tylerroush/2023/11/30/novo-nordisk-sues-two-florida-pharmacies-for-allegedly-selling-impure-weight-loss-drugs/" target="_blank" rel="nofollow noopener noreferrer">Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs</a></h3> <p class="overflow-auto text-[0.95rem] text-light sm:order-3">The Danish drugmaker claims one pharmacy is adding a banned substance to its drugs.</p>  <div class="mt-1 text-sm text-faded sm:order-1 sm:mt-0" title="Nov 30, 2023, 9:59 AM EST">26 days ago - Forbes</div></div></div> </div>  <div class="px-3 xs:px-4 sm:px-0"><button class="mt-4 inline-flex w-full items-center justify-center whitespace-nowrap rounded border border-transparent bg-blue-brand_light px-4 py-2 text-lg font-semibold text-white shadow-sm hover:bg-blue-brand_sharp focus:outline-none focus:ring-2 focus:ring-blue-500" data-svelte-h="svelte-ovme6h">Load More News</button></div></div></div></div></main></div></div>   <footer class="clear-both mt-auto bg-gray-800 dark:bg-neutral-900"><div class="mx-auto max-w-7xl px-5 pt-12 sm:px-6 lg:px-8 lg:pb-8 lg:pt-16"><div class="xl:grid xl:grid-cols-3 xl:gap-8"><div class="grid grid-cols-2 gap-8 xl:col-span-2"><div class="md:grid md:grid-cols-2 md:gap-8"><div data-svelte-h="svelte-4aulao"><h4 class="text-sm font-semibold uppercase tracking-wider text-gray-400 dark:text-dark-400">Sections</h4> <ul class="mt-4 space-y-4 text-gray-300 hover:text-white"><li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/stocks/">Stocks</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/ipos/">IPOs</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/etf/">ETFs</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/blog/">Blog</a></li></ul></div> <div class="mt-12 md:mt-0"><h4 class="text-sm font-semibold uppercase tracking-wider text-gray-400 dark:text-dark-400" data-svelte-h="svelte-1nki7xq">Services</h4> <ul class="mt-4 space-y-4"><li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/pro/" data-svelte-h="svelte-1ind0nt">Stock Analysis Pro</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/pro/the-barbell-investor/" data-svelte-h="svelte-1mw8ozy">The Barbell Investor</a></li> <li data-svelte-h="svelte-jv5tof"><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/subscribe/">Free Newsletter</a></li> <li data-svelte-h="svelte-1g6ai5i"><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/support/">Get Support</a></li></ul></div></div> <div class="md:grid md:grid-cols-2 md:gap-8" data-svelte-h="svelte-6bzfk1"><div><h4 class="text-sm font-semibold uppercase tracking-wider text-gray-400 dark:text-dark-400">Website</h4> <ul class="mt-4 space-y-4"><li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/login/">Login</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/faq/">FAQ</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/changelog/">Changelog</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/sitemap/">Sitemap</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/advertise/">Advertise</a></li></ul></div> <div class="mt-12 md:mt-0"><h4 class="text-sm font-semibold uppercase tracking-wider text-gray-400 dark:text-dark-400">Company</h4> <ul class="mt-4 space-y-4"><li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/about/">About</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/contact/">Contact Us</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/terms-of-use/">Terms of Use</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/privacy-policy/">Privacy Policy</a></li> <li><a class="text-gray-300 hover:text-white dark:text-neutral-200 hover:dark:underline" href="/data-disclaimer/">Data Disclaimer</a></li></ul></div></div></div> <div class="mt-8 xl:mt-0"><h4 class="text-sm font-semibold uppercase tracking-wider text-gray-400 dark:text-dark-400" data-svelte-h="svelte-16157co">Market Newsletter</h4> <p class="mt-4 text-gray-300" data-svelte-h="svelte-4795ly">Daily market news in bullet point format.</p> <form class="mt-4 sm:flex sm:max-w-md" method="POST" action="/subscribe/" data-svelte-h="svelte-1262ecb"><input type="email" name="email" id="email-footer" autocomplete="email" required="" class="placeholder-faded w-full min-w-0 appearance-none rounded-md border border-transparent bg-white px-4 py-2 text-gray-900 focus:border-white focus:outline-none focus:ring-2 focus:ring-white focus:ring-offset-2 focus:ring-offset-gray-800 dark:bg-dark-700 dark:focus:border-neutral-400 dark:focus:ring-neutral-400" placeholder="Enter your email"> <div class="mt-3 rounded-md sm:ml-3 sm:mt-0 sm:shrink-0"><button name="submit" type="submit" class="button text-base font-medium rounded cursor-pointer w-full sm:w-auto">Subscribe</button></div></form></div></div> <div class="mt-8 border-t border-gray-700 pt-8 dark:border-dark-700 md:flex md:items-center md:justify-between"><div class="flex space-x-6 md:order-2"><a href="https://www.facebook.com/stockanalysisoff/" target="_blank" rel="noopener noreferrer" class="text-gray-400 hover:text-gray-300 dark:text-dark-400 dark:hover:text-dark-300" aria-label="Follow on Facebook"><!-- HTML_TAG_START --><svg class="pointer-events-none h-8 w-8" fill="currentColor" viewBox="0 0 24 24" style="max-width:40px" aria-hidden="true"><path fill-rule="evenodd" d="M22 12c0-5.523-4.477-10-10-10S2 6.477 2 12c0 4.991 3.657 9.128 8.438 9.878v-6.987h-2.54V12h2.54V9.797c0-2.506 1.492-3.89 3.777-3.89 1.094 0 2.238.195 2.238.195v2.46h-1.26c-1.243 0-1.63.771-1.63 1.562V12h2.773l-.443 2.89h-2.33v6.988C18.343 21.128 22 16.991 22 12z" clip-rule="evenodd"></path></svg><!-- HTML_TAG_END --></a> <a href="https://twitter.com/stock_analysisx" target="_blank" rel="noopener noreferrer" class="text-gray-400 hover:text-gray-300 dark:text-dark-400 dark:hover:text-dark-300" aria-label="Follow on Twitter"><!-- HTML_TAG_START --><svg class="pointer-events-none h-8 w-8" fill="currentColor" viewBox="0 0 24 24" style="max-width:40px" aria-hidden="true"><path d="M8.29 20.251c7.547 0 11.675-6.253 11.675-11.675 0-.178 0-.355-.012-.53A8.348 8.348 0 0022 5.92a8.19 8.19 0 01-2.357.646 4.118 4.118 0 001.804-2.27 8.224 8.224 0 01-2.605.996 4.107 4.107 0 00-6.993 3.743 11.65 11.65 0 01-8.457-4.287 4.106 4.106 0 001.27 5.477A4.072 4.072 0 012.8 9.713v.052a4.105 4.105 0 003.292 4.022 4.095 4.095 0 01-1.853.07 4.108 4.108 0 003.834 2.85A8.233 8.233 0 012 18.407a11.616 11.616 0 006.29 1.84"></path></svg><!-- HTML_TAG_END --></a></div> <p class="mt-8 text-gray-400 dark:text-dark-400 md:order-1 md:mt-0" data-svelte-h="svelte-1rezeqe">© 2023 Stock Analysis. All rights reserved.</p></div>  <div class="mt-8 border-t border-gray-700 dark:border-dark-700 pt-8 pb-6 text-center text-sm text-gray-400 dark:text-dark-400" data-svelte-h="svelte-h3sc3x">Real-time quotes provided by <a href="https://iexcloud.io/" target="_blank" rel="noopener noreferrer" class="text-gray-300 dark:text-neutral-300 hover:dark:text-neutral-100 hover:text-white underline hover:no-underline">IEX Cloud</a>. Other market data may be delayed by 15 minutes or more.</div></div></footer>    
			
			<script>
				{
					__sveltekit_1rfa0qb = {
						base: new URL("../..", location).pathname.slice(0, -1),
						env: {"PUBLIC_SITE_ENV":"Production","PUBLIC_CFSTREAM":"wss://stockanalysis.com/api","PUBLIC_DIRECTUS_URL":"https://stockanalysis.directus.app","PUBLIC_SUPABASE_ANON_KEY":"eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJyb2xlIjoiYW5vbiIsImlhdCI6MTYzNjYyMDk4OSwiZXhwIjoxOTUyMTk2OTg5fQ.NVyfYZrLeT2Iwus7_l-zurv9-BQWXfbn1huLR5MwQsc","PUBLIC_SUPABASE_URL":"https://auth.stockanalysis.com","PUBLIC_CFAPI":"https://stockanalysis.com/api"}
					};

					const element = document.currentScript.parentElement;

					const data = [{"type":"data","data":{session:null,loc:{co:"FR",isUS:false,isEU:true,isCA:false},theme:void 0},"uses":{}},{"type":"data","data":{info:{type:"stocks",symbol:"nvo",ticker:"NVO",name:"Novo Nordisk",nameFull:"Novo Nordisk A/S",exchange:"NYSE",baseurl:"/stocks/nvo",quote:{c:-.03,cdr:-1,cl:102.71,cp:-.03,days:0,e:true,ec:.16,ecp:.16,ep:102.84,epd:102.84,es:"Pre-market",eu:"Dec 27, 2023, 7:46 AM EST",ex:"NYSE",exp:1703682389523,h:103.13,h52:105.69,l:102.41,l52:65.05,mc:459755713865,ms:"closed",o:102.56,p:102.68,pd:102.68,symbol:"nvo",td:"2023-12-26",ts:1703624402100,u:"Dec 26, 2023, 4:00 PM",v:1841225},state:"normal",archived:false,notice:null,cik:"0000353278",id:"rec99vuqioVk6uxaJ",curr:{dividend:"USD",financial:"DKK",main:"USD",price:"USD"},stream:true,features:{chart:true,dividend:true,employees:true,financials:true,forecast:true,market_cap:true,revenue:true}}},"uses":{"params":["symbol"]}},{"type":"data","data":{marketCap:"459.76B",revenue:"30.42B",revenue_type:"ttm",netIncome:"10.68B",sharesOut:"4.48B",eps:"2.48",peRatio:"41.63",forwardPE:"31.15",dividend:"$0.74 (0.72%)",exDividendDate:"Aug 18, 2023",beta:"0.19",analysts:"Strong Buy",target:"90.13 (-12.22%)",earningsDate:"Jan 31, 2024",description:"Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and h...",infoTable:[{t:"Industry",v:"Biotechnology",u:"stocks/industry/biotechnology"},{t:"Sector",v:"Healthcare",u:"stocks/sector/healthcare"},{t:"Founded",v:1923},{t:"Employees",v:"55,185",u:"stocks/nvo/employees"},{t:"Stock Exchange",v:"NYSE"},{t:"Ticker Symbol",v:"NVO"}],financialIntro:"In 2022, Novo Nordisk's revenue was 176.95 billion, an increase of 25.68% compared to the previous year's 140.80 billion. Earnings were 55.53 billion, an increase of 16.27%.",financialChart:[{year:2016,revenue:111780000000,earnings:37925000000},{year:2017,revenue:111696000000,earnings:38130000000},{year:2018,revenue:111831000000,earnings:38628000000},{year:2019,revenue:122021000000,earnings:38951000000},{year:2020,revenue:126946000000,earnings:42138000000},{year:2021,revenue:140800000000,earnings:47757000000},{year:2022,revenue:176954000000,earnings:55525000000}],analystIntro:"According to 4 analysts, the average rating for NVO stock is \"Strong Buy.\" The 12-month stock price forecast is $90.13, which is a decrease of -12.22% from the latest price.",analystTarget:{target:"$90.13",change:"-12.22%",changeWord:"downside"},analystChart:{strongBuy:2,buy:2,hold:0,sell:0,strongSell:0},news:{exp:1703684147122,data:[{url:"https://www.marketwatch.com/story/novo-nordisk-fda-warn-of-fake-ozempic-6dca2448",img:"https://cdn.snapi.dev/images/v1/w/4/im-31318914size1777777777777778width800-2206812.jpg",title:"Novo Nordisk, FDA warn of fake Ozempic",text:"The U.S. Food and Drug Administration has seized thousands of units of fake Ozempic, the agency said Thursday, warning that some counterfeit units of the Novo Nordisk NVO, -0.15% diabetes drug may sti...",source:"Market Watch",type:"Article",time:"Dec 22, 2023, 1:01 PM EST",ago:"4 days ago"},{url:"https://www.globenewswire.com/news-release/2023/12/22/2800529/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",img:"https://cdn.snapi.dev/images/v1/s/v/press8-2206141.jpg",title:"Novo Nordisk A/S - share repurchase programme",text:"Bagsværd, Denmark, 22 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...",source:"GlobeNewsWire",type:"Article",time:"Dec 22, 2023, 6:52 AM EST",ago:"5 days ago"},{url:"https://reut.rs/3tjXmwV",img:"https://cdn.snapi.dev/images/v1/l/6/l6u7quzijbn5lihsxvjm7cf56i-2100374-2206150.jpg",title:"US FDA warns about counterfeit versions of Novo's diabetes drug Ozempic",text:"The U.S. Food and Drug Administration on Thursday warned consumers not to use counterfeit versions of Novo Nordisk's diabetes drug Ozempic that have been found in the country's drug supply chain.",source:"Reuters",type:"Article",time:"Dec 22, 2023, 3:00 AM EST",ago:"5 days ago"},{url:"https://www.marketwatch.com/story/five-obesity-drug-trends-to-watch-in-2024-who-can-compete-with-eli-lilly-and-novo-nordisk-1dc62a7d",img:"https://cdn.snapi.dev/images/v1/b/n/im-80508866size1777777777777778width800-2203823.jpg",title:"Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?",text:"The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.",source:"Market Watch",type:"Article",tickers:["$LLY","$ALT","$AMGN","$GPCR","$RHHBY","$VKTX"],time:"Dec 20, 2023, 11:17 AM EST",ago:"6 days ago"},{url:"6sLarVG0GAA",img:"https://cdn.snapi.dev/images/v1/m/q/weight-loss-drugs-poised-for-big-2024-as-demand-surges-2203470.jpg",title:"Weight-loss drugs poised for big 2024 as demand surges",text:"CNBC's Karen Gilchrist reviews the growth of the weight-loss drug industry and its outlook for 2024.",source:"CNBC International TV",type:"Video",time:"Dec 20, 2023, 8:25 AM EST",ago:"6 days ago"},{url:"https://www.reuters.com/breakingviews/ozempic-overshoot-will-plump-up-bargain-hunters-2023-12-18/",img:"https://cdn.snapi.dev/images/v1/e/s/esws-2200631.jpg",title:"Ozempic overshoot will plump up bargain-hunters",text:"Weight-loss drug excitement went overboard in 2023. Novo Nordisk's Wegovy – which is known as Ozempic when used to treat diabetes – and Eli Lilly's Zepbound are the first effective treatments for obes...",source:"Reuters",type:"Article",tickers:["$LLY"],time:"Dec 18, 2023, 11:01 AM EST",ago:"8 days ago"},{url:"https://www.forbes.com/sites/roberthart/2023/12/18/fake-wegovy-pharma-giant-novo-nordisk-reportedly-steps-up-efforts-tackling-illegal-weight-loss-drugs-sold-online/",img:"https://cdn.snapi.dev/images/v1/f/6/fake-wegovy-pharma-giant-novo-nordisk-reportedly-steps-up-efforts-tackling-illegal-weight-loss-drugs-sold-online-2199900.jpg",title:"Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online",text:"One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity and ...",source:"Forbes",type:"Article",time:"Dec 18, 2023, 8:02 AM EST",ago:"9 days ago"},{url:"https://www.reuters.com/business/healthcare-pharmaceuticals/novo-owner-commits-265-mln-wegovy-windfall-respiratory-diseases-2023-12-18/",img:"https://cdn.snapi.dev/images/v1/f/r/fre21we-2200044.jpg",title:"Novo owner commits $265 mln of Wegovy windfall to respiratory diseases",text:"The Novo Nordisk Foundation, which controls drug maker Novo Nordisk, said on Monday it would commit up to 1.8 billion Danish crowns ($265 million) to setting up an initiative aimed at improving vaccin...",source:"Reuters",type:"Article",time:"Dec 18, 2023, 2:03 AM EST",ago:"9 days ago"},{url:"https://www.reuters.com/business/healthcare-pharmaceuticals/indiamart-is-working-with-novo-nordisk-halt-illegal-wegovy-sales-source-2023-12-18/",img:"https://cdn.snapi.dev/images/v1/f/e/few2-2199419.jpg",title:"Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -source",text:"Indian online marketplace IndiaMART has been removing unauthorized listings of Novo Nordisk's blockbuster weight-loss drug Wegovy after holding talks with the Danish drugmaker in early October, a sour...",source:"Reuters",type:"Article",time:"Dec 17, 2023, 8:39 PM EST",ago:"9 days ago"},{url:"cr_Bt0WBCcQ",img:"https://cdn.snapi.dev/images/v1/r/e/ozempic-and-wegovy-lead-novo-nordisk-to-yahoo-finances-company-of-the-year-2199308.jpg",title:"Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year",text:"Novo Nordisk (NVO) and more specifically its weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street. The company's financial performance, impact and buzz has...",source:"Yahoo Finance",type:"Video",time:"Dec 17, 2023, 10:00 AM EST",ago:"9 days ago"},{url:"etPOZLei5Ks",img:"https://cdn.snapi.dev/images/v1/g/6/novo-nordisk-everything-investors-need-to-know-2191952.jpg",title:"Novo Nordisk: Everything investors need to know",text:"Yahoo Finance selected pharmaceutical firm Novo Nordisk (NVO) as it's 2023 Company of the Year. Developer of obesity medications Wegovy and Ozempic, Novo Nordisk stock has gained over 40% year-to-date...",source:"Yahoo Finance",type:"Video",time:"Dec 11, 2023, 4:47 PM EST",ago:"15 days ago"},{url:"_d2bgFrVG9U",img:"https://cdn.snapi.dev/images/v1/0/a/novo-nordisk-yahoo-finances-company-of-the-year-2023-2191732.jpg",title:"Novo Nordisk: Yahoo Finance's Company of the Year, 2023",text:"Novo Nordisk (NVO) and more specifically its blockbuster weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street and well beyond this year, due to the company...",source:"Yahoo Finance",type:"Video",time:"Dec 11, 2023, 2:28 PM EST",ago:"15 days ago"},{url:"sqpx0vAuR5Q",img:"https://cdn.snapi.dev/images/v1/p/v/why-novo-nordisks-corporate-structure-stands-out-2191683.jpg",title:"Why Novo Nordisk's corporate structure stands out",text:"Yahoo Finance selected Novo Nordisk (NVO) as its Company of the Year for 2023, and there are plenty of reasons why. One interesting reason some investors may not know about, however, is its unique cor...",source:"Yahoo Finance",type:"Video",time:"Dec 11, 2023, 1:34 PM EST",ago:"15 days ago"},{url:"https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-rivals-explore-booming-weight-loss-drug-market-entry-2023-12-08/",img:"https://cdn.snapi.dev/images/v1/k/9/sm4nxzj3knluvfgclyvi3x4sgu-2189252.jpg",title:"Novo, Lilly rivals explore booming weight-loss drug market entry",text:"Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up thr...",source:"Reuters",type:"Article",tickers:["$LLY"],time:"Dec 8, 2023, 9:58 AM EST",ago:"18 days ago"},{url:"https://www.marketwatch.com/story/goldman-sachs-money-manager-digs-into-three-themes-for-long-term-growth-66add895",img:"https://cdn.snapi.dev/images/v1/3/h/im-60177213size1777777777777778width800-2184207.jpg",title:"Goldman Sachs money manager digs into three themes for long-term growth",text:"Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which...",source:"Market Watch",type:"Article",tickers:["$AXNX","$CAVA","#GSC","$IRTC","$MTH","$SG","$SHAK"],time:"Dec 5, 2023, 11:27 AM EST",ago:"21 days ago"},{url:"https://www.marketwatch.com/story/no-more-exercising-president-rfk-jr-heres-one-banks-outrageous-predictions-for-2024-1bc90579",img:"https://cdn.snapi.dev/images/v1/i/v/im-23070502size1777777777777778width800-2183145.jpg",title:"No more exercising? President RFK Jr.? Here's one bank's outrageous predictions for 2024",text:"Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels will ge...",source:"Market Watch",type:"Article",tickers:["$LLY"],time:"Dec 5, 2023, 5:45 AM EST",ago:"22 days ago"},{url:"https://www.marketbeat.com/originals/ozempic-vs-mounjaro-battle-of-the-bulge/?utm_source=snapi",img:"https://cdn.snapi.dev/images/v1/t/s/med-20231204090609-battle-of-the-bulge-ozempic-vs-2182095.jpg",title:"Ozempic vs. Mounjaro:: Battle of the bulge",text:"The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Nov...",source:"MarketBeat",type:"Article",tickers:["$LLY"],time:"Dec 4, 2023, 10:16 AM EST",ago:"22 days ago"},{url:"https://www.barrons.com/articles/roche-stock-weight-loss-eli-lilly-novo-nordisk-f5fe020f",img:"https://cdn.snapi.dev/images/v1/w/x/drugs18-2181671.jpg",title:"Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.",text:"Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke...",source:"Barrons",type:"Article",tickers:["$LLY","$RHHBY"],time:"Dec 4, 2023, 7:43 AM EST",ago:"23 days ago"},{url:"https://www.marketwatch.com/story/roche-strikes-3-1-billion-deal-to-buy-obesity-drug-maker-carmot-therapeutics-billion-in-race-to-rival-novo-nordisks-ozempic-6b88b8c9",img:"https://cdn.snapi.dev/images/v1/a/e/im-740245size1777777777777778width800-2181363.jpg",title:"Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic",text:"Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen No...",source:"Market Watch",type:"Article",tickers:["$RHHBY"],time:"Dec 4, 2023, 5:40 AM EST",ago:"23 days ago"},{url:"iG7B61u9RNI",img:"https://cdn.snapi.dev/images/v1/m/q/theres-still-a-long-runway-for-obesity-drugs-says-cantor-fitzgeralds-louise-chen-2180112.jpg",title:"There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen",text:"Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, an...",source:"CNBC Television",type:"Video",tickers:["$LLY"],time:"Dec 1, 2023, 12:22 PM EST",ago:"25 days ago"},{url:"https://invezz.com/news/2023/12/01/eli-lilly-novo-nordisk-to-benefit-as-pfizers-weight-loss-drug-implodes/?utm_source=snapi",img:"https://cdn.snapi.dev/images/v1/k/m/pfizer-stock-is-up-about-2-today-2179590.jpg",title:"Eli Lilly, Novo Nordisk to benefit as Pfizer's weight loss drug implodes",text:"Eli Lilly (NYSE: LLY) and Novo Nordisk NYSE: NVO) stock prices have been some of the hottest names in Wall Street. NVO has soared by over 48% this year while LLY has surged by over 61%.",source:"Invezz",type:"Article",tickers:["$LLY","$PFE"],time:"Dec 1, 2023, 7:58 AM EST",ago:"26 days ago"},{url:"https://www.reuters.com/world/maker-wegovy-ozempic-showers-money-us-obesity-doctors-2023-12-01/",img:"https://cdn.snapi.dev/images/v1/a/x/ax5cpy2prfgongj4s5jaz2tmha-2179500.jpg",title:"Maker of Wegovy, Ozempic showers money on U.S. obesity doctors",text:"Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found.",source:"Reuters",type:"Article",time:"Dec 1, 2023, 6:11 AM EST",ago:"26 days ago"},{url:"https://www.barrons.com/articles/weight-loss-stocks-are-getting-pricey-here-are-some-alternatives-b867d642",img:"https://cdn.snapi.dev/images/v1/b/a/bank41-2179543.jpg",title:"Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.",text:"Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to ...",source:"Barrons",type:"Article",tickers:["$LLY"],time:"Dec 1, 2023, 4:30 AM EST",ago:"26 days ago"},{url:"https://www.cnbc.com/2023/11/30/novo-nordisk-sues-pharmacies-over-impure-wegovy-ozempic-dupes.html",img:"https://cdn.snapi.dev/images/v1/3/u/107295103-16935843032023-09-01t154153z-1005718174-rc2yy2ao8b7p-rtrmadp-0-novo-nordisk-lvmh-valuation-2178994.jpeg",title:"Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs",text:"The lawsuits come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in the U.S. due to skyrocketing demand.",source:"CNBC",type:"Article",time:"Nov 30, 2023, 4:57 PM EST",ago:"26 days ago"},{url:"https://www.forbes.com/sites/tylerroush/2023/11/30/novo-nordisk-sues-two-florida-pharmacies-for-allegedly-selling-impure-weight-loss-drugs/",img:"https://cdn.snapi.dev/images/v1/f/a/novo-nordisk-sues-two-florida-pharmacies-for-allegedly-selling-impure-weight-loss-drugs-2178014.jpg",title:"Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs",text:"The Danish drugmaker claims one pharmacy is adding a banned substance to its drugs.",source:"Forbes",type:"Article",time:"Nov 30, 2023, 9:59 AM EST",ago:"26 days ago"}]},chart:{expiration:1703687400000,data:[{t:1703583000,c:102.59,o:102.56},{t:1703583060,c:102.696},{t:1703583120,c:102.696},{t:1703583180,c:102.856},{t:1703583240,c:102.9},{t:1703583300,c:102.86},{t:1703583360,c:102.916},{t:1703583420,c:102.916},{t:1703583480,c:102.79},{t:1703583540,c:102.862},{t:1703583600,c:102.875},{t:1703583660,c:102.74},{t:1703583720,c:102.966},{t:1703583780,c:102.966},{t:1703583840,c:103.02},{t:1703583900,c:102.7},{t:1703583960,c:102.7},{t:1703584020,c:102.75},{t:1703584080,c:102.75},{t:1703584140,c:102.74},{t:1703584200,c:102.74},{t:1703584260,c:102.895},{t:1703584320,c:102.84},{t:1703584380,c:102.823},{t:1703584440,c:102.74},{t:1703584500,c:102.82},{t:1703584560,c:102.82},{t:1703584620,c:102.89},{t:1703584680,c:102.89},{t:1703584740,c:102.98},{t:1703584800,c:102.825},{t:1703584860,c:102.83},{t:1703584920,c:102.86},{t:1703584980,c:102.84},{t:1703585040,c:102.84},{t:1703585100,c:102.88},{t:1703585160,c:102.98},{t:1703585220,c:102.98},{t:1703585280,c:103},{t:1703585340,c:102.96},{t:1703585400,c:102.92},{t:1703585460,c:102.935},{t:1703585520,c:103.025},{t:1703585580,c:102.95},{t:1703585640,c:102.95},{t:1703585700,c:102.957},{t:1703585760,c:102.905},{t:1703585820,c:102.913},{t:1703585880,c:102.99},{t:1703585940,c:103.01},{t:1703586000,c:103.04},{t:1703586060,c:102.97},{t:1703586120,c:102.94},{t:1703586180,c:102.97},{t:1703586240,c:102.98},{t:1703586300,c:102.96},{t:1703586360,c:102.956},{t:1703586420,c:102.96},{t:1703586480,c:102.87},{t:1703586540,c:102.94},{t:1703586600,c:102.94},{t:1703586660,c:102.92},{t:1703586720,c:102.93},{t:1703586780,c:102.93},{t:1703586840,c:102.97},{t:1703586900,c:102.97},{t:1703586960,c:102.94},{t:1703587020,c:102.925},{t:1703587080,c:102.97},{t:1703587140,c:102.93},{t:1703587200,c:102.955},{t:1703587260,c:102.98},{t:1703587320,c:102.969},{t:1703587380,c:102.96},{t:1703587440,c:102.96},{t:1703587500,c:102.95},{t:1703587560,c:102.93},{t:1703587620,c:102.94},{t:1703587680,c:102.94},{t:1703587740,c:102.98},{t:1703587800,c:102.91},{t:1703587860,c:102.85},{t:1703587920,c:102.895},{t:1703587980,c:null},{t:1703588040,c:102.895},{t:1703588100,c:102.895},{t:1703588160,c:102.92},{t:1703588220,c:102.95},{t:1703588280,c:102.89},{t:1703588340,c:102.91},{t:1703588400,c:102.85},{t:1703588460,c:102.84},{t:1703588520,c:102.83},{t:1703588580,c:102.83},{t:1703588640,c:102.85},{t:1703588700,c:102.91},{t:1703588760,c:102.87},{t:1703588820,c:102.915},{t:1703588880,c:102.93},{t:1703588940,c:102.94},{t:1703589000,c:102.97},{t:1703589060,c:103},{t:1703589120,c:103.062},{t:1703589180,c:103.05},{t:1703589240,c:103.1},{t:1703589300,c:103.05},{t:1703589360,c:103.11},{t:1703589420,c:103.06},{t:1703589480,c:103.06},{t:1703589540,c:103.045},{t:1703589600,c:103.025},{t:1703589660,c:102.97},{t:1703589720,c:102.989},{t:1703589780,c:102.96},{t:1703589840,c:102.96},{t:1703589900,c:103.05},{t:1703589960,c:103.06},{t:1703590020,c:103.06},{t:1703590080,c:103.08},{t:1703590140,c:103.07},{t:1703590200,c:103.07},{t:1703590260,c:103.071},{t:1703590320,c:103.02},{t:1703590380,c:103.045},{t:1703590440,c:103.062},{t:1703590500,c:103.07},{t:1703590560,c:null},{t:1703590620,c:103.08},{t:1703590680,c:103.07},{t:1703590740,c:103.1},{t:1703590800,c:103.078},{t:1703590860,c:103.08},{t:1703590920,c:103.075},{t:1703590980,c:103.1},{t:1703591040,c:103.1},{t:1703591100,c:103.02},{t:1703591160,c:103.02},{t:1703591220,c:103},{t:1703591280,c:103},{t:1703591340,c:103},{t:1703591400,c:102.95},{t:1703591460,c:102.97},{t:1703591520,c:102.97},{t:1703591580,c:102.97},{t:1703591640,c:102.995},{t:1703591700,c:102.95},{t:1703591760,c:102.96},{t:1703591820,c:102.965},{t:1703591880,c:103.01},{t:1703591940,c:102.965},{t:1703592000,c:102.962},{t:1703592060,c:102.955},{t:1703592120,c:102.948},{t:1703592180,c:102.948},{t:1703592240,c:102.95},{t:1703592300,c:102.94},{t:1703592360,c:102.94},{t:1703592420,c:102.89},{t:1703592480,c:102.901},{t:1703592540,c:102.95},{t:1703592600,c:102.95},{t:1703592660,c:103.031},{t:1703592720,c:103.031},{t:1703592780,c:103.07},{t:1703592840,c:103.02},{t:1703592900,c:102.99},{t:1703592960,c:102.99},{t:1703593020,c:103.005},{t:1703593080,c:103.01},{t:1703593140,c:103.036},{t:1703593200,c:103.02},{t:1703593260,c:103.01},{t:1703593320,c:103.02},{t:1703593380,c:102.99},{t:1703593440,c:102.99},{t:1703593500,c:103.01},{t:1703593560,c:103.01},{t:1703593620,c:102.98},{t:1703593680,c:102.98},{t:1703593740,c:102.96},{t:1703593800,c:102.925},{t:1703593860,c:102.935},{t:1703593920,c:102.948},{t:1703593980,c:102.985},{t:1703594040,c:102.985},{t:1703594100,c:102.96},{t:1703594160,c:102.95},{t:1703594220,c:102.95},{t:1703594280,c:102.92},{t:1703594340,c:102.86},{t:1703594400,c:102.86},{t:1703594460,c:102.87},{t:1703594520,c:102.9},{t:1703594580,c:102.91},{t:1703594640,c:102.9},{t:1703594700,c:102.9},{t:1703594760,c:102.9},{t:1703594820,c:102.9},{t:1703594880,c:102.9},{t:1703594940,c:102.85},{t:1703595000,c:102.83},{t:1703595060,c:102.83},{t:1703595120,c:102.85},{t:1703595180,c:102.83},{t:1703595240,c:102.765},{t:1703595300,c:102.765},{t:1703595360,c:102.78},{t:1703595420,c:102.769},{t:1703595480,c:102.748},{t:1703595540,c:102.795},{t:1703595600,c:102.795},{t:1703595660,c:102.8},{t:1703595720,c:102.8},{t:1703595780,c:102.8},{t:1703595840,c:102.818},{t:1703595900,c:102.8},{t:1703595960,c:102.775},{t:1703596020,c:102.81},{t:1703596080,c:102.81},{t:1703596140,c:102.8},{t:1703596200,c:102.815},{t:1703596260,c:102.83},{t:1703596320,c:102.8},{t:1703596380,c:102.79},{t:1703596440,c:102.785},{t:1703596500,c:102.8},{t:1703596560,c:102.79},{t:1703596620,c:102.775},{t:1703596680,c:102.795},{t:1703596740,c:102.772},{t:1703596800,c:102.78},{t:1703596860,c:102.785},{t:1703596920,c:102.78},{t:1703596980,c:102.79},{t:1703597040,c:102.795},{t:1703597100,c:102.88},{t:1703597160,c:102.86},{t:1703597220,c:102.88},{t:1703597280,c:102.9},{t:1703597340,c:102.9},{t:1703597400,c:102.92},{t:1703597460,c:102.88},{t:1703597520,c:102.87},{t:1703597580,c:102.87},{t:1703597640,c:102.82},{t:1703597700,c:102.82},{t:1703597760,c:102.83},{t:1703597820,c:102.83},{t:1703597880,c:102.8},{t:1703597940,c:102.83},{t:1703598000,c:102.84},{t:1703598060,c:102.84},{t:1703598120,c:102.82},{t:1703598180,c:102.834},{t:1703598240,c:102.85},{t:1703598300,c:102.84},{t:1703598360,c:102.86},{t:1703598420,c:102.848},{t:1703598480,c:102.85},{t:1703598540,c:102.81},{t:1703598600,c:102.81},{t:1703598660,c:102.79},{t:1703598720,c:102.789},{t:1703598780,c:102.78},{t:1703598840,c:102.77},{t:1703598900,c:102.785},{t:1703598960,c:102.8},{t:1703599020,c:102.77},{t:1703599080,c:102.78},{t:1703599140,c:102.72},{t:1703599200,c:102.72},{t:1703599260,c:102.73},{t:1703599320,c:102.69},{t:1703599380,c:102.73},{t:1703599440,c:102.73},{t:1703599500,c:102.76},{t:1703599560,c:102.76},{t:1703599620,c:102.755},{t:1703599680,c:102.8},{t:1703599740,c:102.81},{t:1703599800,c:102.79},{t:1703599860,c:102.79},{t:1703599920,c:102.79},{t:1703599980,c:102.76},{t:1703600040,c:102.76},{t:1703600100,c:102.76},{t:1703600160,c:102.81},{t:1703600220,c:102.8},{t:1703600280,c:102.78},{t:1703600340,c:102.789},{t:1703600400,c:102.78},{t:1703600460,c:102.78},{t:1703600520,c:102.81},{t:1703600580,c:102.81},{t:1703600640,c:102.805},{t:1703600700,c:102.81},{t:1703600760,c:102.785},{t:1703600820,c:102.785},{t:1703600880,c:102.81},{t:1703600940,c:102.825},{t:1703601000,c:102.825},{t:1703601060,c:102.84},{t:1703601120,c:102.86},{t:1703601180,c:102.895},{t:1703601240,c:102.86},{t:1703601300,c:102.86},{t:1703601360,c:102.907},{t:1703601420,c:102.93},{t:1703601480,c:102.92},{t:1703601540,c:102.92},{t:1703601600,c:102.91},{t:1703601660,c:102.918},{t:1703601720,c:102.93},{t:1703601780,c:102.905},{t:1703601840,c:102.905},{t:1703601900,c:102.91},{t:1703601960,c:102.91},{t:1703602020,c:102.91},{t:1703602080,c:102.905},{t:1703602140,c:102.918},{t:1703602200,c:102.92},{t:1703602260,c:102.89},{t:1703602320,c:102.88},{t:1703602380,c:102.93},{t:1703602440,c:102.94},{t:1703602500,c:102.91},{t:1703602560,c:102.92},{t:1703602620,c:102.9},{t:1703602680,c:102.915},{t:1703602740,c:102.9},{t:1703602800,c:102.88},{t:1703602860,c:102.88},{t:1703602920,c:102.86},{t:1703602980,c:102.86},{t:1703603040,c:102.885},{t:1703603100,c:102.88},{t:1703603160,c:102.9},{t:1703603220,c:102.885},{t:1703603280,c:102.88},{t:1703603340,c:102.81},{t:1703603400,c:102.85},{t:1703603460,c:102.85},{t:1703603520,c:102.835},{t:1703603580,c:102.835},{t:1703603640,c:102.81},{t:1703603700,c:102.81},{t:1703603760,c:102.795},{t:1703603820,c:102.795},{t:1703603880,c:102.87},{t:1703603940,c:102.83},{t:1703604000,c:102.86},{t:1703604060,c:102.86},{t:1703604120,c:102.91},{t:1703604180,c:102.9},{t:1703604240,c:102.88},{t:1703604300,c:102.97},{t:1703604360,c:102.96},{t:1703604420,c:102.96},{t:1703604480,c:102.92},{t:1703604540,c:102.92},{t:1703604600,c:102.91},{t:1703604660,c:102.918},{t:1703604720,c:102.918},{t:1703604780,c:102.89},{t:1703604840,c:102.89},{t:1703604900,c:102.89},{t:1703604960,c:102.85},{t:1703605020,c:102.855},{t:1703605080,c:102.84},{t:1703605140,c:102.8},{t:1703605200,c:102.79},{t:1703605260,c:102.8},{t:1703605320,c:102.8},{t:1703605380,c:102.785},{t:1703605440,c:102.79},{t:1703605500,c:102.79},{t:1703605560,c:102.815},{t:1703605620,c:102.845},{t:1703605680,c:102.798},{t:1703605740,c:102.875},{t:1703605800,c:102.835},{t:1703605860,c:102.81},{t:1703605920,c:102.795},{t:1703605980,c:102.785},{t:1703606040,c:102.74},{t:1703606100,c:102.75},{t:1703606160,c:102.705},{t:1703606220,c:102.7},{t:1703606280,c:102.69},{t:1703606340,c:102.68},{t:1703606400,c:102.68}]}},"uses":{"params":["symbol"]}}];

					Promise.all([
						import("../../_app/immutable/entry/start.a887d5f0.js"),
						import("../../_app/immutable/entry/app.6ed667cc.js")
					]).then(([kit, app]) => {
						kit.start(app, element, {
							node_ids: [0, 13, 103],
							data,
							form: null,
							error: null
						});
					});
				}
			</script>
		</div>
	

</body></html>